Ascentage Pharma Group International American Depository Shares
AAPG
Closed
$18.89
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. The company is headquartered in Suzhou, Jiangsu and currently employs 767 full-time employees. The company went IPO on 2019-10-28. The firm's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The firm's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The firm primarily conducts its businesses in domestic market.
Key stats
Open
$18.00
Volume
9.04K
Market cap
$1.92B
Prev. close
$18.89
Impl / hst vl
-
Open interest
$0.00
$17.61
Day’s Range
$19.00
$16.36
52W Range
$28.81
Valuation
50
Valuation score
Fairly Valued
P/E
-
P/S
19.70
P/B
8.54
Current ratio
1.79
Debt / Equity
-0.37
ROE
-124.87%
Gross margin
91.98%
Income growth
10.36%
FCF growth
65.77
Analysts estimates
Consensus rating
Buy
The average rating from top 6 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$51.14
The top 7 analysts forecasts that 12-month price may increase by 170.70%, with a low of $37.86 and a high of $63.02
$37.86
Low
$51.14
Avg
$63.02
High
Current price
Earnings
Q4 ‘25 revenue
$50.09M
Q4 ‘25 net income
-$95.94M
Revenue
Net income
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply